Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone Microcirculation Study in T2D
NCT00676260Phase 2Completed
- Sponsor
- Takeda
- Start
- Dec 2002
- Primary completion
- Aug 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Pioglitazone QD with Placebo QD (2 arms). Primary endpoint: Capillary filtration capacity at 10 weeks. Started Dec 2002; status: completed.
02
Drugs
pioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00676260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00676260.